• Endari Now Available by Prescription in US for Sickle Cell Disease Treatment
  • FDA Grants Breakthrough Therapy Designation to Voxelotor
  • Emmaus Helping Sickle Cell Disease Patients Outside US Obtain Early Access to Its Therapy
  • Bluebird Bio Presents Positive Early Results of Gene Therapy LentiGlobin for Sickle Cell Disease
  • Novartis Therapy Crizanlizumab Prolongs Time to First Sickle Cell Pain Crisis, Study Finds
  • Voxelotor Improves Sickle Cell Disease of 83% of Adolescents in Phase 2a Trial
  • Prolong Completes Enrolling Patients in Phase 2 Trial of Sickle Cell Disease Therapy Sanguinate
  • Increasing Doses of Hydroxyurea Benefits Young Sickle Cell Patients
  • CTX001 to Be Developed as Gene-Editing Therapy for Sickle Cell Disease
  • Intellia Uses Gene Editing to Replace Defective Blood Component in Sickle Cell Disease
  • Sickle Cell Disease Patients Use Opioids More When Experiencing Negative Emotions, Study Finds
  • New Online Platform Created to Support Sickle Cell Disease Community